2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2006091034v1 18/3/975    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coyne, D. W. Search for Related Content PubMed PubMed Citation Articles by Coyne, D. W.

Ferric Gluconate Is Highly Efficacious in Anemic Hemodialysis Patients with High Serum Ferritin and Low Transferrin Saturation: Results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study

Daniel W. Coyne^*, Toros Kapoian, Wadi Suki, Ajay K. Singh, John E. Moran^||, Naomi V. Dahl^¶, Adel R. Rizkala^¶ and the DRIVE Study Group

^* Department of Medicine, Washington University School of Medicine, St. Louis, Missouri; Department of Medicine, University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School, New Brunswick, New Jersey; The Kidney Institute, Inc., Houston, Texas; Department of Medicine, Harvard Medical School, Boston, Massachusetts; ^|| Satellite Healthcare, Inc., Mountain View, California; and ^¶ Clinical Affairs, Watson Laboratories, Inc., Morristown, New Jersey

Address correspondence to: Dr. Daniel W. Coyne, Washington University School of Medicine, 660 S. Euclid Avenue, Campus Box 8129, St. Louis, MO 63110. Phone: 314-362-7211; Fax: 314-747-3743; E-mail: dcoyne{at}im.wustl.edu

Received for publication September 21, 2006. Accepted for publication December 11, 2006.

Few data exist to guide treatment of anemic hemodialysis patients with high ferritin and low transferrin saturation (TSAT). The Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) trial was designed to evaluate the efficacy of intravenous ferric gluconate in such patients. Inclusion criteria were hemoglobin 11 g/dl, ferritin 500 to 1200 ng/ml, TSAT 25%, and epoetin dosage 225 IU/kg per wk or 22,500 IU/wk. Patients with known infections or recent significant blood loss were excluded. Participants (n = 134) were randomly assigned to no iron (control) or to ferric gluconate 125 mg intravenously with eight consecutive hemodialysis sessions (intravenous iron). At randomization, epoetin was increased 25% in both groups; further dosage changes were prohibited. At 6 wk, hemoglobin increased significantly more (P = 0.028) in the intravenous iron group (1.6 ± 1.3 g/dl) than in the control group (1.1 ± 1.4 g/dl). Hemoglobin response occurred faster (P = 0.035) and more patients responded after intravenous iron than in the control group (P = 0.041). Ferritin 800 or >800 ng/ml had no relationship to the magnitude or likelihood of responsiveness to intravenous iron relative to the control group. Similarly, the superiority of intravenous iron compared with no iron was similar whether baseline TSAT was above or below the study median of 19%. Ferritin decreased in control subjects (–174 ± 225 ng/ml) and increased after intravenous iron (173 ± 272 ng/ml; P < 0.001). Intravenous iron resulted in a greater increase in TSAT than in control subjects (7.5 ± 7.4 versus 1.8 ± 5.2%; P < 0.001). Reticulocyte hemoglobin content fell only in control subjects, suggesting worsening iron deficiency. Administration of ferric gluconate (125 mg for eight treatments) is superior to no iron therapy in anemic dialysis patients receiving adequate epoetin dosages and have a ferritin 500 to 1200 ng/ml and TSAT 25%.

This article has been cited by other articles:

				S. B. Silverstein, J. A. Gilreath, and G. M. Rodgers Intravenous Iron Therapy: A Summary of Treatment Options and Review of Guidelines Journal of Pharmacy Practice, December 1, 2008; 21(6): 431 - 443. [Abstract] [PDF]

				F. Locatelli, A. Covic, K.-U. Eckardt, A. Wiecek, R. Vanholder, and on behalf of the ERA-EDTA ERBP Advisory Board Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP) Nephrol. Dial. Transplant., November 26, 2008; (2008) gfn653v1. [Full Text] [PDF]

				M. Rambod, C. P. Kovesdy, and K. Kalantar-Zadeh Combined High Serum Ferritin and Low Iron Saturation in Hemodialysis Patients: The Role of Inflammation Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1691 - 1701. [Abstract] [Full Text] [PDF]

				S. A. Browne and D. Reddan Potential role of bone morphogenetic protein (BMP) signalling as a potential therapeutic target for modification of iron balance Nephrol. Dial. Transplant., October 2, 2008; (2008) gfn551v1. [Full Text] [PDF]

				K.-L. Kuo, S.-C. Hung, Y.-H. Wei, and D.-C. Tarng Intravenous Iron Exacerbates Oxidative DNA Damage in Peripheral Blood Lymphocytes in Chronic Hemodialysis Patients J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1817 - 1826. [Abstract] [Full Text] [PDF]

				S. Tomasello Anemia of Chronic Kidney Disease Journal of Pharmacy Practice, June 1, 2008; 21(3): 181 - 195. [Abstract] [PDF]

				M. Auerbach Should Intravenous Iron Be the Standard of Care in Oncology? J. Clin. Oncol., April 1, 2008; 26(10): 1579 - 1581. [Full Text] [PDF]

				S. S Shord, J.M. Hamilton Jr, and S. Cuellar Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia Journal of Oncology Pharmacy Practice, March 1, 2008; 14(1): 5 - 22. [Abstract] [PDF]

				T. Kapoian, N. B. O'Mara, A. K. Singh, J. Moran, A. R. Rizkala, R. Geronemus, R. C. Kopelman, N. V. Dahl, and D. W. Coyne Ferric Gluconate Reduces Epoetin Requirements in Hemodialysis Patients with Elevated Ferritin J. Am. Soc. Nephrol., February 1, 2008; 19(2): 372 - 379. [Abstract] [Full Text] [PDF]

				N. B. O'Mara Anemia in Patients With Chronic Kidney Disease Diabetes Spectr, January 1, 2008; 21(1): 12 - 19. [Abstract] [Full Text] [PDF]

				R. Agarwal, J. L. Davis, and L. Smith Serum Albumin Is Strongly Associated with Erythropoietin Sensitivity in Hemodialysis Patients Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 98 - 104. [Abstract] [Full Text] [PDF]

				I. Lenga, C. Lok, R. Marticorena, J. Hunter, N. Dacouris, and M. Goldstein Role of Oral Iron in the Management of Long-Term Hemodialysis Patients Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 688 - 693. [Abstract] [Full Text] [PDF]

				C. Gilmartin Pharmacist's role in managing anemia in patients with chronic kidney disease: Potential clinical and economic benefits Am. J. Health Syst. Pharm., July 1, 2007; 64(13_Supplement_8): S15 - S22. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673